/SNGX
SNGX Stock - Soligenix, Inc.
Healthcare|BiotechnologyNASDAQ
$1.38+12.20%
+$0.15 (+12.20%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.52
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.37 – $1.39
TARGET (TP)$1.59
STOP LOSS$1.27
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.85
52W High$6.23
52W Low$1.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $250,000 | $33,351 | $1.93M |
| Gross Profit | $-119,371 | $-742,048 | $-300,822 | $-695,289 | $109,584 |
| Gross Margin | N/A | N/A | -120.3% | -2084.8% | 5.7% |
| Operating Income | $-9,439,497 | $-7,697,940 | $-14,238,904 | $-13,098,960 | $-18,586,507 |
| Net Income | $-8,266,576 | $-6,140,730 | $-13,798,339 | $-12,550,973 | $-17,688,522 |
| Net Margin | N/A | N/A | -5519.3% | -37633.0% | -916.3% |
| EPS | $-4.98 | $-12.66 | $-76.96 | $-67.54 | $-154.45 |
Company Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SNGXBeat Rate
61%
Last 18 quarters
Avg Surprise
-5.3%
EPS vs Estimate
Beats / Misses
11/6
1 met exactly
Latest EPS
$-0.58
Q4 2025
EPS Surprise History
Q1 24
+15.8%
$-2.56vs$-3.04
Q2 24
+10.0%
$-2.88vs$-3.20
Q3 24
+37.9%
$-1.31vs$-2.11
Q4 24
+28.4%
$-0.78vs$-1.09
Q1 25
-20.0%
$-1.14vs$-0.95
Q2 25
-58.2%
$-1.06vs$-0.67
Q3 25
-3.8%
$-0.82vs$-0.79
Q4 25
+7.9%
$-0.58vs$-0.63
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 20, 2026 | $-0.27 | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.63 | $-0.58 | +7.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.79 | $-0.82 | -3.8% | ✗ MISS |
Q2 2025 | May 9, 2025 | $-0.67 | $-1.06 | -58.2% | ✗ MISS |
Q1 2025 | Mar 21, 2025 | $-0.95 | $-1.14 | -20.0% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-1.09 | $-0.78 | +28.4% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-2.11 | $-1.31 | +37.9% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-3.20 | $-2.88 | +10.0% | ✓ BEAT |
Q1 2024 | Mar 15, 2024 | $-3.04 | $-2.56 | +15.8% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-7.04 | $-2.56 | +63.6% | ✓ BEAT |
Q3 2023 | Aug 21, 2023 | $-7.84 | $-2.72 | +65.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-20.00 | $-5.76 | +71.2% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-1.12 | $-4.58 | -308.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-19.19 | $-19.19 | 0.0% | = MET |
Q3 2022 | Aug 12, 2022 | $-16.79 | $-14.39 | +14.3% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-14.39 | $-23.99 | -66.7% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-19.19 | $-26.39 | -37.5% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-31.18 | $-21.59 | +30.8% | ✓ BEAT |
Q3 2021 | Aug 13, 2021 | $-26.39 | $-11.99 | +54.6% | ✓ BEAT |
Latest News
Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford)
📈 PositiveBenzinga•Dec 18, 2025, 12:35 PM
Soligenix Announced Extended Results Of Its Ongoing Phase 2a Trial Of SGX302 (Synthetic Hypericin) For Mild-to-moderate Psoriasis
📈 PositiveBenzinga•Dec 17, 2025, 12:34 PM
Soligenix Completes Planned Enrollment Of 50 Patients Necessary For Interim Analysis In 80 Patient Confirmatory Phase 3 Double-Blind, Placebo-Controlled Study Evaluating HyBryte In CTCL Treatment
📈 PositiveBenzinga•Nov 19, 2025, 12:33 PM
Soligenix Q3 EPS $(0.58) Misses $(0.56) Estimate
📉 NegativeBenzinga•Nov 7, 2025, 12:40 PM
Soligenix Updates U.S. Medical Advisory Board To Guide Phase 3 HyBryte Development For CTCL
➖ NeutralBenzinga•Oct 14, 2025, 11:33 AM
Soligenix shares are trading higher after the company reported no safety concerns in first DMC review of phase 3 HyBryte trial for CTCL.
📈 PositiveBenzinga•Oct 7, 2025, 04:09 PM
Soligenix Reports No Safety Concerns In First DMC Review Of Phase 3 HyBryte Trial For CTCL
📈 PositiveBenzinga•Oct 7, 2025, 11:33 AM
Soligenix Expands European MAB To Provide Addl Medical/Clinical Strategic Guidance As It Advances Confirmatory Phase 3 Placebo-Controlled Study Evaluating Safety And Efficacy Of HyBryte In CTCL Treatment
📈 PositiveBenzinga•Sep 30, 2025, 11:36 AM
Soligenix shares are trading lower after the company announced it priced its $7.5 million offering.
📉 NegativeBenzinga•Sep 26, 2025, 01:24 PM
Soligenix stock down after pricing $7.5M public offering to raise capital
📉 NegativeSeeking Alpha•Sep 26, 2025, 10:48 AM
Soligenix Prices $7.5M Offering At $1.35; 5,555,560 Shares And 5-Year Warrants; 1,162,064 Existing Warrants Repriced; Closing Sept 29, 2025
➖ NeutralBenzinga•Sep 26, 2025, 10:36 AM
SNGX stock has given up its prior gain. Soligenix shares were trading higher after the company appointed former White House economic adviser Tomas J.
➖ NeutralBenzinga•Sep 23, 2025, 12:02 PM
Soligenix shares are trading higher after the company appointed former White House economic adviser Tomas J. Philipson as a strategic advisor.
📈 PositiveBenzinga•Sep 23, 2025, 11:31 AM
Soligenix Appoints Former White House Economic Adviser Tomas J. Philipson As A Strategic Advisor
📈 PositiveBenzinga•Sep 23, 2025, 11:31 AM
Soligenix Publishes Study Proving Long-Term Stability Of ThermoVax Ebola Vaccines
📈 PositiveBenzinga•Sep 4, 2025, 11:33 AM
'Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years'- Science Direct
📈 PositiveBenzinga•Sep 3, 2025, 06:14 PM
Watching Soligenix; Zacks Small-Cap Research Gives Stock $35.00 Price Valuation
📈 PositiveBenzinga•Aug 20, 2025, 03:00 PM
Soligenix shares are trading higher after the company announced it was granted FDA orphan drug designation for Dusquetide.
📈 PositiveBenzinga•Aug 18, 2025, 02:54 PM
Soligenix Granted FDA Orphan Drug Designation To Dusquetide, The Active Ingredient In SGX945, For Behçet's Disease Treatment
📈 PositiveBenzinga•Aug 18, 2025, 11:31 AM
Soligenix Receives Nasdaq Notice For Non-Compliance With Equity Requirement
📉 NegativeBenzinga•Aug 15, 2025, 09:42 PM
Frequently Asked Questions about SNGX
What is SNGX's current stock price?
Soligenix, Inc. (SNGX) is currently trading at $1.38 per share. The stock has moved +12.20% today.
What is the analyst price target for SNGX?
No analyst price targets are currently available for this stock.
What sector is Soligenix, Inc. in?
Soligenix, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SNGX's market cap?
Soligenix, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does SNGX pay dividends?
No, Soligenix, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.88
Mkt Cap: $0.0B
QLGN
Qualigen Therapeutics, Inc.
$3.21
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
XBIO
Xenetic Biosciences, Inc.
$2.15
Mkt Cap: $0.0B
Explore stocks similar to SNGX for comparison